Patricia LoRusso

1995–2025 年に発表

199
論文数
29,522
被引用数
91
h 指数
188
i10 指数

被引用数

Patricia LoRusso の年別被引用数1997 年: 被引用 1 件1998 年: 被引用 3 件1999 年: 被引用 4 件2000 年: 被引用 9 件2001 年: 被引用 14 件2002 年: 被引用 30 件2003 年: 被引用 64 件2004 年: 被引用 80 件2005 年: 被引用 100 件2006 年: 被引用 103 件2007 年: 被引用 101 件2008 年: 被引用 104 件2009 年: 被引用 106 件2010 年: 被引用 204 件2011 年: 被引用 214 件2012 年: 被引用 261 件2013 年: 被引用 336 件2014 年: 被引用 380 件2015 年: 被引用 380 件2016 年: 被引用 378 件2017 年: 被引用 385 件2018 年: 被引用 353 件2019 年: 被引用 1,094 件2020 年: 被引用 1,171 件2021 年: 被引用 1,145 件2022 年: 被引用 975 件2023 年: 被引用 802 件2024 年: 被引用 1,250 件2025 年: 被引用 870 件2026 年: 被引用 28 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 4,365 件、この内訳の 28.6%中国: 引用元論文 1,811 件、この内訳の 11.9%イギリス: 引用元論文 903 件、この内訳の 5.9%イタリア: 引用元論文 812 件、この内訳の 5.3%ドイツ: 引用元論文 704 件、この内訳の 4.6%フランス: 引用元論文 610 件、この内訳の 4%カナダ: 引用元論文 493 件、この内訳の 3.2%スペイン: 引用元論文 487 件、この内訳の 3.2%日本: 引用元論文 433 件、この内訳の 2.8%オーストラリア: 引用元論文 420 件、この内訳の 2.8%オランダ: 引用元論文 357 件、この内訳の 2.3%スイス: 引用元論文 351 件、この内訳の 2.3%
0%28.6%その他 23.1%

分野

  • Medicine53.2%
  • Biochemistry, Genetics and Molecular Biology32.1%
  • Immunology and Microbiology4.8%
  • Materials Science4.4%
  • Engineering1.2%
  • Neuroscience1.1%
  • その他3.2%

トピック

  • Cancer Immunotherapy and Biomarkers4%
  • HER2/EGFR in Cancer Research3.8%
  • Lung Cancer Treatments and Mutations2.9%
  • Monoclonal and Polyclonal Antibodies Research2.4%
  • Nanoparticle-Based Drug Delivery2.1%
  • RNA Interference and Gene Delivery2%
  • その他82.8%

共著者

全論文

検索で開く
  1. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 294

  2. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Zhen Shi, Sandhya Mandlekar, Mark T. Lin, Stephanie Royer‐Joo, Julie Chang, Tomi Jun, Neekesh V. Dharia, Jennifer L. Schutzman, GO42144 Investigator and Study Group, Sae-Won Han - Nature Medicine 2023 被引用: 122

  3. The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development

    著者: , , , , - Cancer Discovery 2024 被引用: 186

  4. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

    著者: , , , , , , , , - The Lancet Oncology 2017 被引用: 523

  5. Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors

    著者: - Journal of Clinical Oncology 2016 被引用: 489

  6. BET inhibitors: a novel epigenetic approach

    著者: , , - Annals of Oncology 2017 被引用: 367

  7. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Cancer Immunology Immunotherapy 2023 被引用: 109

  8. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 被引用: 127

  9. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study

    著者: , , , , , , , , , - Targeted Oncology 2014 被引用: 210

  10. Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eleni Lagkadinou, Kate Sasser, Özlem Türeci, Ulf Forssmann, Tahamtan Ahmadi, Uğur Şahin, Maria Jure‐Kunkel, Ignacio Melero - Cancer Discovery 2022 被引用: 113

  11. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2012 被引用: 1,119

  12. First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2013 被引用: 699

  13. The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

    著者: , , , , , , , , , , - Cancer Discovery 2023 被引用: 92

  14. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

    著者: , , , , , , , , - The Lancet Oncology 2014 被引用: 716

  15. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors

    著者: , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2023 被引用: 63

  16. 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer

    著者: , , , , , , , , , , , , , , , , - Clinical Cancer Research 2017 被引用: 368

  17. Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2019 被引用: 286

  18. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Raid Aljumaily, Ignacio Melero, Rachel Lubong Sabado, Ina Rhee, Michael R. Mancuso, Lars Müller, Gregg Fine, Mahesh Yadav, Leesun Kim, Vincent J. P. Leveque, Alberto Robert, Martine Darwish, Ting Qi, Jiawen Zhu, Jingbin Zhang, Patrick Twomey, Gautham K. Rao, Donald W. Low, Christoph Petry, Amy A. Lo, Jill Schartner, Lélia Delamarre, Ira Mellman, Martin Löwer, Felicitas Müller, Evelyna Derhovanessian, Andrea Cortini, Luisa Manning, Daniel Maurus, Sebastian Brachtendorf, Verena Lörks, Tana Omokoko, Eva Godehardt, Dirk Becker, Christine Hawner, Christine Wallrapp, Christian Albrecht, Christoph Kröner, Arbel D. Tadmor, Jan Diekmann, Mathias Vormehr, Anette Jork, Anna Paruzynski, Maren Lang, Jonathon Blake, Oliver Hennig, Andreas N. Kuhn, Uğur Şahin, Özlem Türeci, D. Ross Camidge - Nature Medicine 2025 被引用: 96

  19. A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas

    著者: , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 91

  20. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , - JAMA Oncology 2015 被引用: 839

  21. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 被引用: 435

  22. Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials

    著者: , , , , , , , , - British Journal of Cancer 2020 被引用: 120

  23. Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2022 被引用: 63

  24. First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Haley Laken, Richard Murray, Elizabeth Trehu, Christopher J. Harvey - Clinical Cancer Research 2022 被引用: 97